We read every 13F, Form 4, and catalyst filing from 15specialist biotech funds. You get the signal, the context, and the “so what” — every Monday in your inbox.
$29/mo after trial · Cancel anytime · No credit card to start
Tracking $73.4B+ in biotech fund positions across 15 specialist hedge funds
15
Specialist Funds
tracked quarterly
843+
Biotech Companies
cross-referenced
465+
Active Catalysts
PDUFAs, Phase 2/3
$73.4B
Tracked Positions
in fund holdings
Funds we track
The data is public. The interpretation is the product.
Real signals from SEC filings, updated daily.Last updated: Mar 29, 2026
Step 01
13F holdings, Form 4 insider trades, activist stakes, and clinical trial data. We parse thousands of SEC filings so you never have to open EDGAR again.
Step 02
An insider sold shares? We'll tell you if it was a routine 10b5-1 plan or a real conviction trade. Every signal gets a two-sentence analyst note explaining why it matters.
Step 03
Your weekly brief arrives before the market opens. Personalized to your watchlist. The rest of the week, you just invest.
Except the analyst reads every SEC filing, tracks every catalyst, and never takes a day off. For less than a nice dinner.
Never miss a position change from Baker Bros, Perceptive, OrbiMed, or any of the 15 funds we track. New positions, increases, trims, and exits — the moment they file.
When 3+ specialist funds independently buy the same stock, something is happening. We surface this automatically — no cross-referencing 15 separate filings.
A fund bought shares. So what? Our AI reads the catalyst calendar, cash position, and insider activity, then tells you why it matters.
PDUFA dates, Phase 3 readouts, AdCom meetings — with outcome tracking. Know what's coming before the market does.
Which of your holdings has 2 quarters of cash left? We pull burn rates from 10-Q filings so you see dilution risk before the offering drops.
Star a ticker. Get an email when Baker Bros takes a position, an insider buys, or a catalyst date moves. Your portfolio, monitored.
Built on SEC EDGAR filings, ClinicalTrials.gov data, and FDA calendar events. Updated daily. Contextualized by AI.
Academic evidence behind the signals. Why insider trades, 13F filings, and fund convergence predict biotech returns.
One plan. Full access. Cancel anytime.
7-day free trial included
No credit card required to start
Not investment advice. Data sourced from public SEC filings.
All data is sourced directly from SEC EDGAR filings (13F, Form 4, 13D/13G), ClinicalTrials.gov for catalyst events, and FDA calendar dates. We parse and normalize the raw filings automatically.
Form 4 insider signals and 13D/G activist stakes are ingested daily. 13F fund positions are updated quarterly as funds file. Catalyst data is refreshed weekly from ClinicalTrials.gov.
We track 15 specialist biotech hedge funds including Baker Brothers, Perceptive Advisors, OrbiMed, RA Capital, and more. These are funds with deep biotech expertise and concentrated portfolios.
They're databases. We're the analyst who reads the database and writes you a brief. WhaleWisdom shows you that a fund holds a stock. We tell you how much, whether they're adding or trimming, what catalyst is coming, and what their insider is doing with their own money. The difference is between data and insight.
Yes. Cancel from your dashboard at any time. No contracts, no commitments. Your access continues through the end of your billing period.
The AI context is generated from structured data — SEC filings, clinical trial records, and financial metrics. It summarizes what the data shows, not predictions. Think of it as having an analyst read every filing for you and write a 2-sentence brief.
When 3 or more specialist biotech funds independently build positions in the same company, it signals high institutional conviction. We surface this automatically — no manual cross-referencing across fund filings.
Every fund position. Every insider trade. Every catalyst. Contextualized, filtered, and in your inbox Monday morning.
Start 7-Day Free Trial$29/mo after trial · Cancel anytime
Not ready to commit? Get the free weekly brief: